OncoMatch/Clinical Trials/NCT03936153

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Is NCT03936153 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies abexinostat for diffuse large b-cell lymphoma (dlbcl).

Phase 2RecruitingXynomic Pharmaceuticals, Inc.NCT03936153Data as of May 2026

Treatment: abexinostat — An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Check if I qualify

Extracted eligibility criteria

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Max 2 prior lines

Min 2 prior lines

Must have received: anti-CD20 antibody

including anti- cluster of differentiation antigen (anti-CD20) antibody

Must have received: cytotoxic chemotherapy

including...cytotoxic therapy

Cannot have received: steroid hormone

Have received steroid hormone...within a specified amount of time per protocol

Cannot have received: chemotherapy

Have received...chemotherapy...within a specified amount of time per protocol

Cannot have received: targeted therapy

Have received...targeted therapy...within a specified amount of time per protocol

Cannot have received: radiotherapy

Have received...radiotherapy...within a specified amount of time per protocol

Cannot have received: antibody-based therapies

Have received...antibody-based therapies...within a specified amount of time per protocol

Cannot have received: autologous stem cell transplant

Have received autologous stem cell transplant...within a certain amount of time as specified in protocol

Cannot have received: allogeneic stem cell transplant

Have received...allogeneic stem cell transplant within a certain amount of time as specified in protocol

Lab requirements

Blood counts

Meet various hematological lab parameters

Kidney function

Meet various renal function lab parameters

Liver function

Meet various liver function lab parameters

Cardiac function

Have any cardiac impairment as defined per protocol

Meet various hematological, liver and renal function lab parameters. Have any cardiac impairment as defined per protocol

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify